Author

M. Fratello

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Federico· 3 shared A. Pavel· 3 shared A. Serra· 3 shared D. Greco· 3 shared G. del Giudice· 3 shared L. A. Saarimaki· 2 shared A. Di Lieto· 1 shared B. Fadeel· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

A. Federico

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A network toxicology approach for mechanistic modelling of nanomaterial hazard and adverse outcomes

G. del Giudice, A. Serra, A. Pavel, M. Torres Maia, L. A. Saarimäki, M. Fratello, A. Federico, H. Alenius, B. Fadeel, D. Greco

This paper develops a network-based toxicology approach to model nanomaterial hazard by linking molecular changes to adverse outcomes in biological systems.

Advanced Science · Aug 1, 2024Peer-reviewedPharmacology & Toxicology

Molecular annotation of AOPs guides the development of the next generation mechanistic chemical safety assessment and new approach methods

L. A. Saarimaki, J. Morikka, A. Pavel, S. Korpilahde, G. del Giudice, A. Federico, M. Fratello, A. Serra, D. Greco

This paper develops a framework to annotate Adverse Outcome Pathways (AOPs) using molecular data, enabling better integration of toxicogenomics into chemical safety assessment.

bioRxiv · Jul 8, 2022 · PreprintPharmacology & Toxicology

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

A. Serra, M. Fratello, A. Federico, R. Ojha, R. Provenzani, E. Tasnadi, L. Cattelani, G. del Giudice, P. A. S. Kinaret, L. A. Saarimaki, A. Pavel, V. Cerullo, O. Vapalahti, P. Horvath, A. Di Lieto, , D. Greco

The paper identifies two compounds that inhibit SARS-CoV-2 infection and syncytia formation through computational prioritization and in vitro testing.

bioRxiv · Apr 15, 2021Pharmacology & Toxicology